Related by context. All words. (Click for frequent words.) 84 Marketing Authorization Application 80 Marketing Authorisation Application 75 Biologics License Application BLA 72 Marketing Authorisation Application MAA 72 Application MAA 72 New Drug Application 71 Biologics License Application 71 supplemental Biologics License Application 70 Marketing Authorization 69 Application BLA 69 Biologic License Application 68 sNDA 68 sBLA 68 Premarket Approval PMA 68 Market Authorization Application 67 Rhucin R 67 Marketing Authorization Applications 66 MAA submission 66 Biologic License Application BLA 66 Mutual Recognition Procedure 66 BLA filing 66 application sNDA 66 commercialize oritavancin 66 FIRAZYR 66 SYCREST 65 Cellegesic 65 IND Investigational New 65 Preotact 65 CONBRIZA 65 Orathecin 65 JOULFERON 65 Premarket Approval Application 65 Biological License Application 65 Marketing Authorisation 64 Complete Response 64 Loramyc R 64 Drug Submission 64 Market Approval PMA 64 FDA Approvable Letter 64 Orphan Drug Status 64 Investigational Device Exemption 64 Orphan Drug status 64 liver resection surgeries 64 StaphVAX R 64 Decentralized Procedure 64 Pivotal Phase III 64 OMP designation 64 Zenvia ™ 64 orphan designation 64 Rhucin 64 oral ridaforolimus 64 European Medicines Evaluation 63 Centralized Procedure 63 FDA approvable letter 63 Preotact R 63 Syndrome LEMS 63 vinorelbine emulsion 63 BLA submission 63 Pirfenidone 63 eprodisate KIACTA TM 63 Voraxaze 63 Phase III pivotal 63 Nexavar ® 63 Icatibant 63 Raptiva R 63 Fodosine 63 GTC recombinant form 63 HP Acthar Gel repository 63 NDA submission 63 Ceplene 63 Medicinal Products EMEA 63 Scientific Advice 63 Rhucin ® 63 Alvesco R 63 alvimopan 63 Clinical Trial Application 63 HFA MDI 63 CIP TRAMADOL ER 63 Soliris TM eculizumab 62 Loramyc 62 Firdapse 62 GATTEX TM 62 histamine dihydrochloride 62 Pixuvri 62 Mepact 62 Trobalt 62 FOLOTYN ® 62 Phase III clinical 62 CryoSeal FS System 62 Zingo TM 62 Tostrex 62 Telavancin 62 CHMP recommendation 62 Investigational Device Exemption IDE 62 Toctino R 62 APF# NDA 62 Civacir 62 PREOS R 62 ZEGERID Capsules 62 MONOVISC 62 Joulferon 62 COMFORT II 62 Receives Positive Opinion 62 submitted Marketing Authorization 62 FDA Accepts 62 Dyloject TM 62 supplemental biologics 62 sNDA submission 62 Orphan Status 62 Loramyc ® 62 Complete Response letter 62 CHMP opinion 62 Junovan 62 corticotropin injection 62 Zenpep 62 severe hypercholesterolemia 62 phase IIb clinical 62 Evoltra TM 62 ZEGERID Chewable Tablets 62 acyclovir Lauriad R 62 pivotal Phase III 61 ruxolitinib 61 PMA submission 61 Orphan Drug designation 61 VIVITROL ® 61 Lambert Eaton Myasthenic 61 Oracea TM 61 Aryplase 61 Renvela 61 Ruconest 61 methylnaltrexone bromide 61 Phase III Clinical Trial 61 registrational 61 Azilect ® 61 GTC recombinant human 61 Rectogesic 61 Ciclesonide 61 Fast Track Status 61 MEPACT 61 BYETTA ® 61 VALSTAR 61 phase IIb trial 61 Keppra ® XR 61 markets HP Acthar 61 Evoltra R 61 ALVESCO R 61 Augment Bone Graft 61 Movectro 61 FDA Complete Response 61 PREOS 61 SEBIVO 61 Phase III clinical trials 61 CAMPATH R 61 confirmatory Phase III 61 Positive Opinion 61 ATryn R 61 Mycograb 61 Oracea ® 61 Abstral 61 Phase IIa trial 61 Ceftobiprole 61 Somatuline R Autogel R 61 Onco TCS 61 Emezine 61 TEMODAL 61 highly purified pasteurized 61 Phase IIIb clinical 61 ZALBIN 60 Evoltra 60 Raptiva ® 60 Receives Orphan Drug Designation 60 Adenuric R 60 Brilique 60 desvenlafaxine 60 subcutaneous formulation 60 TAXUS Element Stent System 60 Nebido 60 Alitretinoin 60 REBETOL combination therapy 60 Approvable letter 60 Dacogen injection 60 Fast Track designation 60 dalbavancin 60 Ranolazine 60 Febuxostat 60 XIAFLEX ™ 60 NEBIDO 60 Rhucin ® recombinant 60 Zevtera ™ 60 PNP inhibitor 60 Fortigel 60 Zebinix R 60 Aloxi R 60 balsalazide tablet 60 T Pred 60 Files Investigational 60 Zalbin 60 THELIN 60 OMAPRO ™ 60 ILUVIEN ® 60 Orphan Drug Designation 60 Luveniq 60 Oncoscience AG 60 FACTIVE R gemifloxacin 60 methylnaltrexone 60 Alvesco 60 orphan medicinal product 60 sapropterin dihydrochloride 60 human C1 inhibitor 60 rolling Biologics License 60 Zensana 60 Angiox 60 Retacrit 60 Tracleer r 60 IND submission 60 OFIRMEV 60 BENLYSTA 60 Firdapse ™ amifampridine phosphate 60 Pivotal Trial 60 DORIBAX 60 Frova ® 60 registrational trial 60 k premarket 60 Corlux 60 Ixempra 60 post operative ileus 60 Peginterferon alfa 2b 60 Ereska 60 NDA Submission 60 PIX# trial 60 Cimzia TM 60 acyclovir Lauriad ® 60 Iluvien ® 60 Telatinib 60 Neupro R 60 Firazyr 60 silodosin 60 hoFH 60 Mycamine 60 Omigard 60 Impax ANDA 60 Ketotransdel 60 ezogabine 60 Ganite R 60 NYSE Amex PTN 60 Orphan Medicinal Product 60 Announces Tentative Approval 59 Synvisc One 59 Augment Injectable 59 Drug Eluting Stent System 59 testosterone gel LibiGel 59 Thalidomide Pharmion 59 cutaneous T cell 59 Phase IIIb study 59 miconazole MBT 59 Certican 59 Ambrisentan 59 subcutaneous RELISTOR 59 FOSRENOL 59 telavancin NDA 59 Ceplene R 59 NEBIDO R 59 Receives Marketing Authorization 59 Toctino ® 59 submitted Biologics License 59 granulated mesalamine 59 Cimzia ® certolizumab pegol 59 SPRYCEL ® 59 sumatriptan DosePro 59 Silenor ® doxepin 59 CIMZIA r 59 Phase III Trial 59 Afinitor ® 59 mesylate tablets 59 Cladribine Tablets 59 Sycrest 59 Approvable Letter 59 Increlex TM 59 Genasense ® 59 Biologics Licensing 59 Plenaxis R 59 Dalbavancin 59 cSSTI 59 Kuvan R 59 intravenous acetaminophen 59 EOquin 59 Torisel 59 Alvesco ® 59 Esbriet pirfenidone 59 RELISTOR ® 59 octreotide implant 59 Dupuytren Contracture 59 ELIQUIS 59 sitaxsentan sodium 59 Release Capsules 59 Esbriet ® 59 Increlex R 59 Phase IIb Trial 59 XIAFLEX ® 59 Flutiform ™ 59 Ganite ® 59 miconazole Lauriad R 59 Inhalation Aerosol 59 initiate Phase IIb 59 Phase Ib study 59 Satraplatin 59 Qutenza 59 R bendamustine hydrochloride 59 PDX pralatrexate 59 AZILECT ® 59 cell lymphoma CTCL 59 BRILINTA 59 oral methylnaltrexone 59 JZP 59 Fibrillex TM 59 aztreonam lysine 59 lymphoma CTCL 59 Dyloject 59 novel bactericidal 59 ARCOXIA 59 Fast Track Designation 59 Eloxatin ® 59 intravenous iclaprim 59 Thelin tm 59 cutaneous T 59 tiapamil 59 Cimzia ® 59 Vascular Wrap TM 59 Levoleucovorin 59 Acetavance TM 59 vinflunine 59 BROMDAY 59 ZEVALIN ® 59 Vimpat ® lacosamide 59 refractory chronic lymphocytic 59 ecallantide 59 ULTRASE 59 sevelamer carbonate 59 Basilea Toctino R 59 PROVENGE ® 59 Nabi HB Intravenous 59 PEGINTRON TM 59 ABILIFY R 59 paliperidone palmitate 59 CRMD# 59 Diabetic Macular Edema 59 Actemra tocilizumab 59 alogliptin 59 ATPace TM 59 pseudobulbar affect PBA 59 generation purine nucleoside 59 Metformin GR 59 Ceplene TM 59 Phase 2b clinical 59 investigational antiplatelet agent 59 Pafuramidine 59 Marketing Approval PMA 59 rasagiline tablets 59 XiDay 59 peginesatide 59 REPLAGAL 59 investigational pan BCR 59 Firazyr ® 59 Supplemental Biologics License Application 59 Ventavis 59 GRAS notification 58 ZEFTERA ™ 58 Barr ANDA 58 Kristalose ® lactulose 58 Mylan Receives Approval 58 Somatuline R Depot 58 Kamada AAT 58 dextromethorphan quinidine 58 Liberte TM 58 Prestara TM 58 Neupro ® 58 SCHWARZ PHARMA 58 Nexavar sorafenib 58 Plicera 58 SUPPRELIN R LA 58 motexafin gadolinium Injection 58 intravenous formulation 58 LEUKINE 58 Submits Supplemental 58 TSX SHQ 58 Neupro 58 sorafenib tablets 58 LIALDA 58 Xyrem ® 58 phase IIa clinical 58 oritavancin 58 proprietary transdermal patch 58 Renvela ® 58 ZEGERID Powder 58 Sular formulation 58 Cleviprex TM clevidipine 58 Firdapse TM amifampridine phosphate 58 albinterferon alfa 2b 58 VISICOL R 58 sNDAs 58 Drug Application 58 SUMAVEL 58 PROSTASCINT R 58 Abstral ® 58 therefore therapeutically equivalent 58 Onalta ™ 58 IV acetaminophen 58 solifenacin succinate 58 Kit CD# positive 58 Cloretazine ® 58 FUSILEV ® 58 SUTENT ® 58 interferon gamma 1b 58 Gendux 58 Viviant 58 TAXUS Element Paclitaxel Eluting 58 CDP# 58 diarrhea predominant irritable 58 Panzem R 58 MOZOBIL 58 PecFent 58 POSIDUR TM 58 cUTI 58 Decentralized Procedure DCP 58 confirmatory Phase 3 58 Safinamide 58 nasal calcitonin product 58 Pruvel 58 SAFLUTAN 58 miconazole Lauriad ® 58 Bendamustine 58 cinacalcet HCl 58 virus HCV protease inhibitor 58 Nivestim 58 RANK Ligand inhibitor 58 Phase 2a clinical 58 overactive bladder AA# 58 Soliris eculizumab 58 Orphan Drug designations 58 Glybera R 58 Dapagliflozin 58 Dexilant 58 Phase IIb clinical 58 Orphan Designation 58 JZP 6 58 Personalized Immunotherapy 58 Amrubicin 58 Zelrix 58 ANTEGREN 58 lucinactant 58 Vimpat lacosamide 58 OLpur TM H2H 58 Ceplene ® histamine dihydrochloride 58 SNT MC# 58 MEZAVANT 58 Granted Orphan Drug 58 experimental immunotherapeutics antivirals AmpligeGI mucosa resulting 58 ATryn ® GTC recombinant 58 Allovectin 7 r 58 Romiplostim 58 Zavesca r 58 Phase Ib IIa 58 INDs 58 Tibotec Therapeutics division 58 NOXAFIL 58 SWX BSLN 58 Phase III Clinical Trials 58 PDE4 inhibitor 58 treat opioid induced 58 XIBROM 58 Pirespa 58 RSR# 58 TELINTRA 58 Omigard TM 58 ZEFTERA TM 58 sublingual tablets 58 Advagraf 58 Extended Release Capsules 58 ACOMPLIA R 58 Lubiprostone 58 Kynapid 58 Sanvar R 58 Investigational 58 QNEXA ® 58 Patient Enrollment 58 FlutiformTM 58 USFDA approval 58 KRYSTEXXA TM pegloticase 58 Phase IIb trials 58 Tracleer R 58 SUCCEED trial 58 Release Tablets 58 Deferiprone 58 Allovectin 7 58 Evoltra ® 58 Serdolect ® 57 ADVEXIN p# therapy 57 Phase #b/#a clinical 57 fluvoxamine maleate 57 ferumoxytol Injection 57 Valtropin 57 Kuvan TM sapropterin 57 Vernakalant 57 KALBITOR ® 57 European Medicines Agency 57 Xcytrin R 57 MyVax R 57 Submits Investigational 57 Initiates Enrollment 57 Sebivo 57 Zolpimist 57 PDUFA Date 57 Aloxi ® 57 Phase IIb trial 57 ITAX 57 Entocort 57 Rifaximin 57 PROMUS Element Stent System 57 Bronchitol 57 Methylnaltrexone 57 Submits NDA 57 Completes Patient Enrollment 57 REVLIMID lenalidomide 57 Auxilium Pharma 57 R bivalirudin 57 LUCASSIN 57 CHMP 57 Gel repository corticotropin injection 57 sNDA filing 57 ANDA containing 57 L MTP PE 57 Fludara ® 57 Accelerated Approval 57 oral iron chelator 57 severe gastroparesis 57 pancreatic enzyme replacement 57 relapsed refractory multiple myeloma 57 inhaled formulation 57 Anturol TM 57 naproxen esomeprazole magnesium 57 Qutenza TM 57 Topical Interferon Alpha 2b 57 ketolide antibiotic 57 Oracea 57 FIRMAGON R 57 Relistor 57 Entereg TM 57 INSPIRE Trial Phase III 57 LymphoStat B TM 57 lexidronam injection 57 Certolizumab pegol 57 forodesine 57 bazedoxifene 57 Anturol ® 57 KIACTA ™ 57 SmPC 57 Expanded Indication 57 CE Marked 57 #D#C# 57 FDA APPROVES 57 Orphan designation 57 injectable formulation 57 pivotal Phase 57 NASDAQ ISTA 57 Ranexa R 57 Besivance 57 branded Rectogesic 57 PROVENGE sipuleucel T 57 lorcaserin NDA 57 XAGRID 57 Serostim ® 57 DIFICID ™ 57 Cetrorelix 57 Monovisc 57 Exocrine Pancreatic Insufficiency 57 Fibrin Pad 57 ATryn ® 57 amifampridine phosphate 57 ONGLYZA ™ 57 docetaxel Taxotere R 57 ENTEREG ® 57 Reloxin ® 57 Troxatyl 57 ponatinib 57 MOVIPREP R 57 Entereg R 57 teduglutide 57 Revolade 57 OPAXIO 57 Receives Orphan Drug 57 Opterone R 57 Aloxi Injection 57 R sorafenib tablets 57 Orapred ODT 57 herpetic keratitis 57 investigational humanized monoclonal antibody 57 Junovan TM 57 oxymorphone ER 57 Zevtera TM 57 TRISENOX 57 oral prodrug 57 vapreotide acetate 57 StaphVAX 57 TRISENOX ® 57 Esbriet 57 Glatiramer Acetate 57 RoACTEMRA 57 PROVIGIL 57 IL# PE#QQR 57 dirucotide 57 COLAZAL R 57 GENTAMICIN SURGICAL IMPLANT 57 Roflumilast 57 granted Ortec 57 Complete Response Letter 57 TheraCIM 57 depressive episodes associated 57 BioGlue ® 57 Thrombin topical Recombinant 57 Arzerra ofatumumab 57 NASDAQ SHPGY 57 DC Bead 57 Clevudine 57 ocular formulation 57 apaziquone 57 Extavia 57 Intermezzo ® NDA 57 rALLy clinical trial 57 mifamurtide 57 DAYTRANA TM 57 prGCD 57 QNEXA 57 single injection viscosupplement 57 Oracea R 57 satraplatin 57 Eligard ® 57 rheumatoid arthritis psoriatic arthritis 57 REPEL CV 57 Phase IIb Clinical Trial 57 leading oral taxane 57 Troxatyl TM 57 LibiGel NDA 57 TRANSDUR Bupivacaine 57 SEROQUEL XR 57 Japanese Encephalitis vaccine 57 Act PDUFA date 57 Silenor ® 57 Hexvix ® 57 Oral Calcitonin 57 NDA resubmission 57 ThermoDox ® 57 Clolar ® 57 Phase IIb clinical trials 57 BENLYSTA ® 57 Meets Primary Endpoint 57 Augment TM 57 Initiates Phase II 57 Complicated Skin 57 postoperative ileus POI 57 ARIKACE 57 Vicinium TM 57 Metastatic Colorectal Cancer 56 Zenvia Phase III 56 Zerenex 56 LE SN# 56 BREAKYL 56 REVLIMID R 56 Bayer Nexavar 56 LUVENIQ 56 Pennsaid 56 levocetirizine 56 Cinryze TM 56 phase IIb 56 SABER ™ 56 PrevOnco 56 Exalgo 56 Multaq dronedarone 56 SUPPRELIN LA 56 Rescula 56 FOSAMAX PLUS D 56 daily tramadol 56 lintuzumab SGN 56 induced macular edema 56 anticancer compound 56 ORENCIA ® 56 Advexin 56 Vitrasert R 56 Vasovist 56 Solzira TM 56 AVASTIN 56 Degarelix 56 pantoprazole sodium 56 Loramyc ™ 56 Generic Version 56 Hexvix 56 injection USP 56 GATTEX ™ 56 Intravenous Hepatitis B 56 Pegloticase 56 Onbrez Breezhaler 56 arsenic trioxide injection 56 Amoxicillin PULSYS 56 injectable enzyme 56 Pivotal Phase 56 IMA# 56 oral rivaroxaban 56 Biologics License Applications 56 human antithrombin 56 OsseoFix 56 gastrointestinal disorders characterized 56 Cladribine 56 Cimzia certolizumab pegol 56 docetaxel Taxotere ® 56 LidoPAIN SP 56 alitretinoin 56 refractory Hodgkin lymphoma 56 Phase Ib II 56 MabCampath 56 Velac 56 CoreValve System 56 Lodotra 56 Accelerated Assessment 56 personalized cellular immunotherapy 56 Master File DMF 56 CytoFab 56 Phase IIa 56 commercializing Loramyc ® 56 OvaRex ® MAb 56 XIAPEX 56 Moxatag 56 Inc. NASDAQ HITK 56 topically applied SEPA 56 Glargine 56 New Drug IND 56 Campath ® 56 indiplon capsules 56 Ceplene ® 56 GENERIC SILDENAFIL SOFT Generic 56 Zytiga 56 Initiate Clinical Trial 56 TRANSDUR Sufentanil 56 Extended Release Tablets 56 ENRICH trial 56 CAELYX 56 Fenoglide 56 Tarceva TM 56 phase Ib clinical 56 miconazole Lauriad 56 Sanctura XR 56 Xenazine ® 56 rotigotine transdermal patch 56 SUMAVEL DosePro 56 vertebral augmentation 56 OLEPTRO TM 56 XL# anticancer compounds 56 Fast Track designations 56 SANVAR 56 Tracleer ® 56 Ketotransdel ® 56 Onrigin 56 AMITIZA lubiprostone 56 eltrombopag 56 submit Biologics License 56 Lamictal ODT 56 CLIA waiver 56 Horizant 56 ANDA submission 56 IIa trial 56 Rapydan 56 Xibrom QD 56 XIAPEX ® 56 Bonefos 56 Flutiform 56 Phase 2b study 56 Roche PEGASYS R 56 Lovaza TM 56 ADVANCE PD 56 AMEX IVX LSE IVX.L 56 ADVEXIN 56 Cefprozil 56 Aclasta Reclast 56 Velaglucerase Alfa 56 nanofiltered plasma derived 56 HepeX B TM 56 ORTHOVISC mini 56 Surgical Adhesive 56 PhosLo R 56 JAK inhibitor 56 opioid induced bowel dysfunction 56 REG1 Anticoagulation System 56 diabetic neuropathic pain 56 postherpetic neuralgia PHN 56 AZILECT R 56 Fortical R 56 transfusional iron overload 56 Ferumoxytol 56 Ticagrelor 56 Angiox R 56 MK #B 56 Ustekinumab 56 WILEX 56 gepirone ER 56 EFAPROXYN 56 Feraheme ® 56 Soriatane 56 atypical antipsychotic medication 56 Sancuso 56 investigational pharmacologically unique 56 CERVARIX R 56 Pivotal Study 56 opioid induced constipation OIC 56 Toctino ® alitretinoin 56 SILENOR TM 56 Yondelis ® 56 Itopride 56 VIAject R 56 mitogen activated ERK kinase 56 THALOMID 56 Receives Approvable Letter 56 NVA# 56 Insegia 56 SinuNase ™ 56 IND CTA 56 Teysuno 56 PreHistin TM 56 Alogliptin 56 Manja Bouman CEO 56 Shigamabs ® 56 SinuNase 56 Triage Stroke Panel 56 Nasdaq PGNX today 56 Tolvaptan 56 SinuNase TM 56 NADiA ProsVue 56 HYVISC R 56 memantine HCl 56 ofatumumab HuMax CD# 56 MoxDuo IR 56 Proquin XR 56 ONSOLIS 56 taliglucerase alfa 56 velaglucerase alfa 56 IV APAP 56 Initiate Phase 56 BEMA Fentanyl 56 RECOTHROM R 56 Files IND 56 delivers fluocinolone acetonide FA 56 Premarket Approval 56 Polymer Microspheres 56 Saphris 56 Staphylococcus aureus Polysaccharide Conjugate 56 ABRAXANE ® 56 ELACYT 56 SILENOR 56 indacaterol 56 DPX Survivac 56 Allovectin 7 R 56 Vimovo 56 Phase 2b kidney transplant 56 ZOLINZA 56 Tasigna nilotinib 56 REMOXY R 56 Mirapexin 56 Phase III trials 56 Exelbine 55 Kiadis Pharma 55 phase IIa 55 Orazol 55 Tezampanel 55 NasdaqGM NTEC today 55 novel emulsion formulation 55 Silodosin 55 submitted Marketing Authorisation 55 Submits Response 55 TRANSDUR ® 55 topical gel formulation 55 Sestamibi 55 Stavzor 55 Somatuline Depot 55 Noxafil 55 oral hydromorphone 55 PrandiMet 55 Nasdaq OSCI 55 Oral BDP 55 EOquin TM 55 AMITIZA R 55 Neuromodulation System 55 CLARITY study 55 Premarket Notification 55 Calcium Acetate 55 Combination REOLYSIN R 55 TORISEL 55 Friedreich Ataxia FRDA 55 investigational compound 55 GEM OS1 55 PROMACTA 55 TYGACIL 55 OraTest 55 formerly LymphoStat B 55 Pivotal Clinical Trial 55 Initiates Phase III 55 Tyvaso 55 Polyphenon ® E 55 Increlex ® 55 Telzir 55 casopitant 55 octreotide acetate 55 LEVADEX ™ 55 Victoza liraglutide 55 evaluating satraplatin 55 unique alkylating agent 55 Synvisc ONE 55 Velcade bortezomib 55 XIAFLEX TM 55 By JAMAAL ABDUL 55 Urocidin TM 55 diabetic peripheral neuropathic pain 55 Biopartners 55 Metformin HCl 55 Angiox ® 55 Linjeta TM 55 ELADUR ™ 55 Aclasta 55 IPLEX 55 Entereg 55 Xolegel 55 Efient 55 Dabigatran etexilate 55 TRANSDUR ™ 55 YONDELIS 55 CORTOSS 55 Filgrastim 55 Patient Enrolment 55 Immune Globulin Human 55 Phase 1b trial 55 UPLYSO 55 pioglitazone HCl 55 ANDA Filing 55 Marqibo 55 OLEPTRO 55 GEM #S 55 Vion Pharmaceuticals 55 Aplenzin 55 LibiGel ® 55 pivotal bioequivalence 55 IND Application 55 Tracleer ® bosentan 55 Serdolect 55 Extina 55 Uvidem 55 Xeloda ® 55 label Lipofen R 55 REMOXY NDA 55 ARIXTRA R 55 Augment ™ 55 Divalproex Sodium 55 CUSTOM III 55 DRAXIMAGE 55 Expedited Review 55 Fx #A 55 Liprotamase 55 histone deacetylase HDAC inhibitor 55 Phase Ib 55 candidate NGX 55 NUEDEXTA ™ 55 Alzhemed TM 55 UCB Pharma SA 55 FASLODEX 55 Antegren 55 Nasdaq VRTX 55 hydrochloride tablets 55 TFAS TM 55 Zactima 55 Azilect R 55 male hypogonadism PRO 55 Taiho Pharmaceutical 55 relapsed multiple myeloma 55 Arixtra 55 Glybera 55 PrevOnco ™ 55 PDUFA date 55 Microplasmin 55 VANTAS 55 Wyeth Torisel 55 clofarabine 55 relapsing remitting MS RRMS 55 PHASE III 55 Votrient 55 targeted radiotherapeutic 55 SOLTAMOX TM tamoxifen citrate 55 received CE Conformite 55 Rebif ® 55 TYZEKA 55 forodesine HCl 55 DepoDur 55 Receives CE Marking 55 candidate AQ4N 55 opioid induced constipation